1. Which of the following correctly describes the structural organization of the voltage-gated sodium channel alpha subunit and the molecular basis of fast inactivation?
A) The alpha subunit consists of two transmembrane domains, each containing five segments; fast inactivation is mediated by extracellular calcium binding to a conserved selectivity filter between the two domains
B) The alpha subunit is a single transmembrane segment with a large intracellular N-terminal domain; fast inactivation occurs when the N-terminal domain folds back and occludes the cytoplasmic face of the pore after each action potential
C) The alpha subunit consists of four homologous domains (DI–DIV), each containing six transmembrane segments; the S4 segment of each domain serves as the voltage sensor, and the intracellular loop connecting DIII and DIV contains the isoleucine-phenylalanine-methionine (IFM) motif that occludes the pore during fast inactivation
D) The alpha subunit consists of six transmembrane domains arranged in a single pseudotetrameric ring; the S1–S2 segments form the voltage sensor and the S5–S6 segments contain the inactivation gate on the extracellular surface
E) The alpha subunit is a heterodimer of two identical subunits, each contributing three transmembrane segments; fast inactivation is mediated by phosphorylation of the intracellular loop by protein kinase A following each depolarization event
ANSWER: C
Rationale:
Option C is correct. The voltage-gated sodium channel alpha subunit is a single large transmembrane protein containing four homologous domains (DI through DIV), each consisting of six transmembrane segments (S1 through S6). The S4 segment of each domain bears positively charged arginine and lysine residues that move outward in response to membrane depolarization, acting as the voltage sensor that triggers channel opening. The ion-conducting pore is lined by the S5–S6 segments and the P-loop between them. The molecular basis of fast inactivation is the intracellular loop connecting DIII and DIV, which contains the hydrophobic isoleucine-phenylalanine-methionine (IFM) motif; within 1–2 milliseconds of channel opening, this loop swings inward and physically occludes the cytoplasmic mouth of the pore, producing the fast-inactivated state from which channels cannot conduct sodium until the membrane repolarizes. Understanding this architecture is essential for appreciating why phenytoin and carbamazepine, which bind preferentially to the fast-inactivated state, selectively suppress high-frequency epileptic firing.
Option A: Option A is incorrect. The Nav channel alpha subunit does not consist of two transmembrane domains, and fast inactivation is not mediated by extracellular calcium binding. The four-domain, 24-segment structure is fundamental to Nav channel biology; the two-domain description more closely resembles voltage-gated potassium channels, which assemble as tetramers of single-domain subunits. Fast inactivation is an intracellular event, not an extracellular calcium-dependent process.
Option B: Option B is incorrect. The Nav channel alpha subunit is not a single transmembrane segment with a large N-terminal domain. N-terminal ball-and-chain inactivation is the mechanism used by certain potassium channels (Kv channels), not sodium channels. Nav channel fast inactivation uses the DIII–DIV linker IFM motif, which is an intracellular loop between two of the four domains — a mechanistically and structurally distinct process.
Option D: Option D is incorrect. The Nav channel alpha subunit does not consist of six independent transmembrane domains arranged in a ring, and the inactivation gate is not on the extracellular surface. The four-domain architecture with six segments per domain (totaling 24 transmembrane segments in one contiguous polypeptide) is the correct structure. Placing the inactivation gate extracellularly contradicts both the established topology of Nav channels and the known cytoplasmic location of the IFM loop.
Option E: Option E is incorrect. The Nav channel alpha subunit is not a heterodimer, and fast inactivation is not mediated by protein kinase A phosphorylation after each action potential. Phosphorylation can modulate Nav channel gating over longer timescales as a regulatory mechanism, but it is not the millisecond-scale process responsible for action potential repolarization and the refractory period. The homodimeric description does not correspond to any known Nav channel architecture.
2. Which enzymes are primarily responsible for phenytoin metabolism, at what plasma concentration range does saturation of these enzymes occur, and what is the pharmacokinetic consequence of that saturation?
A) Phenytoin is metabolized primarily by CYP2C9 and secondarily by CYP2C19; these enzymes become saturated within the therapeutic range at concentrations of approximately 5–10 mg/L, at which point elimination shifts from first-order to zero-order kinetics and small dose increments produce disproportionately large rises in steady-state plasma concentration
B) Phenytoin is metabolized primarily by CYP3A4 and secondarily by CYP2D6; saturation occurs at supratherapeutic concentrations above 25 mg/L, so zero-order kinetics is a toxicity phenomenon rather than a routine clinical concern at therapeutic doses
C) Phenytoin is metabolized by UGT1A4 via glucuronidation; saturation occurs at concentrations above 30 mg/L, and the clinical consequence is accumulation of the glucuronide conjugate rather than the parent compound
D) Phenytoin undergoes spontaneous non-enzymatic hydrolysis at physiological pH; the rate of hydrolysis is concentration-independent, making phenytoin unique among anti-seizure drugs in having truly zero-order kinetics at all plasma concentrations regardless of dose
E) Phenytoin is metabolized equally by CYP2C9 and CYP3A4; because CYP3A4 is not saturable at clinical doses, the CYP3A4 pathway provides a pharmacokinetic escape valve that buffers against toxicity when CYP2C9 becomes saturated
ANSWER: A
Rationale:
Option A is correct. Phenytoin is metabolized primarily by CYP2C9, which is responsible for the majority of its hydroxylation to the inactive para-hydroxyphenyl metabolite (5-(p-hydroxyphenyl)-5-phenylhydantoin, or p-HPPH), with CYP2C19 contributing a smaller but clinically relevant fraction. The Michaelis constant (Km) of CYP2C9 for phenytoin lies within or below the therapeutic plasma concentration range — approximately 5–10 mg/L for most individuals — meaning the enzymes approach saturation during normal therapeutic use. Once enzyme capacity is saturated, phenytoin elimination follows zero-order kinetics: a fixed amount of drug (not a fixed fraction) is eliminated per unit time, regardless of concentration. The clinical consequence is that dose increments above the saturation threshold produce disproportionately large and unpredictable increases in steady-state plasma concentration, making small dose adjustments potentially dangerous. This kinetic property is the primary reason phenytoin dose changes must be made in small increments (25–50 mg) with adequate time between adjustments.
Option B: Option B is incorrect. CYP3A4 is not the primary enzyme for phenytoin metabolism — CYP2C9 is. CYP2D6 plays essentially no role in phenytoin metabolism. The claim that saturation occurs only above 25 mg/L is incorrect and clinically dangerous; the saturation threshold lies within the therapeutic range (5–10 mg/L), which is precisely why zero-order kinetics is a routine clinical concern during therapeutic use, not a phenomenon limited to toxicity.
Option C: Option C is incorrect. Phenytoin is not primarily metabolized by UGT1A4 glucuronidation. Glucuronidation is the dominant elimination pathway for drugs such as lamotrigine; phenytoin's primary metabolic route is CYP2C9-mediated hydroxylation. The claim that saturation occurs above 30 mg/L is also incorrect and would imply that routine dosing is safe from non-linear kinetics, which contradicts established clinical pharmacology.
Option D: Option D is incorrect. Phenytoin does not undergo spontaneous non-enzymatic hydrolysis as its primary elimination pathway. Its metabolism is entirely enzymatic (CYP2C9 and CYP2C19), and zero-order kinetics applies only above the enzyme saturation threshold, not at all plasma concentrations. True concentration-independent (zero-order) kinetics throughout all dose ranges is seen with zero-order infusions or with drugs where metabolism is a minor pathway.
Option E: Option E is incorrect. CYP3A4 is not an equal partner with CYP2C9 in phenytoin metabolism, and the concept of a pharmacokinetic escape valve via CYP3A4 does not exist for phenytoin. CYP2C9 dominates phenytoin clearance, and there is no compensatory CYP3A4 pathway that prevents accumulation when CYP2C9 is saturated. If CYP3A4 provided a reliable escape mechanism, phenytoin's zero-order kinetic hazard would be substantially mitigated — which it is not in clinical practice.
3. In what units is fosphenytoin dosed, what is the maximum recommended intravenous infusion rate, and how does this rate compare to intravenous phenytoin?
A) Fosphenytoin is dosed in milligrams of the prodrug itself; the maximum IV infusion rate is 25 mg/min, which is slower than intravenous phenytoin (50 mg/min) because the prodrug requires additional time for plasma phosphatase hydrolysis before pharmacological activity begins
B) Fosphenytoin is dosed in international units (IU) calibrated to enzyme activity of plasma phosphatases; the maximum infusion rate is 100 IU/min and is equivalent to phenytoin infusion because both agents carry the same propylene glycol vehicle
C) Fosphenytoin is dosed in milligrams of elemental phenytoin; the maximum IV rate is 50 mg/min, identical to phenytoin, because fosphenytoin is simply a more soluble salt form with no pharmacokinetic distinction from the parent compound
D) Fosphenytoin is dosed in millimoles per kilogram to account for molecular weight differences between the prodrug and phenytoin; the maximum infusion rate is weight-based at 2 mmol/kg/min and cannot be directly compared to the flat-rate phenytoin infusion
E) Fosphenytoin is dosed in phenytoin sodium equivalents (PE), where 1 mg PE equals the amount of fosphenytoin that yields 1 mg of phenytoin after hydrolysis; the maximum IV infusion rate is 150 mg PE/min — three times faster than the 50 mg/min maximum for intravenous phenytoin — because fosphenytoin lacks the propylene glycol vehicle responsible for cardiac arrhythmias and purple glove syndrome
ANSWER: E
Rationale:
Option E is correct. Fosphenytoin is dosed in phenytoin sodium equivalents (PE) to allow direct conversion from phenytoin dosing without requiring dose recalculation — a critical safety feature in emergency settings where the wrong conversion could produce under- or overdosing. One milligram PE is defined as the amount of fosphenytoin that yields 1 mg of phenytoin after complete plasma phosphatase hydrolysis. The maximum recommended intravenous infusion rate for fosphenytoin is 150 mg PE/min in adults, which is three times faster than the 50 mg/min maximum for intravenous phenytoin. This faster permissible rate exists because intravenous phenytoin is formulated in propylene glycol at alkaline pH; rapid phenytoin infusion drives cardiovascular toxicity (hypotension, arrhythmias) and local reactions (including purple glove syndrome) that are directly attributable to the propylene glycol vehicle. Fosphenytoin is water-soluble, does not require propylene glycol, and is therefore tolerated at substantially higher infusion rates. Fosphenytoin can also be administered intramuscularly, a route that is contraindicated for phenytoin due to crystallization and muscle necrosis.
Option A: Option A is incorrect. Fosphenytoin is not dosed in milligrams of the prodrug itself, and its maximum infusion rate is not slower than phenytoin. The PE dosing system was specifically designed to eliminate confusion about molecular weight differences between fosphenytoin and phenytoin. The premise that the prodrug nature slows the permissible infusion rate is inverted — it is the absence of propylene glycol in fosphenytoin that permits a faster infusion rate than phenytoin.
Option B: Option B is incorrect. Fosphenytoin is not dosed in international units, which are units of biological activity reserved for hormones, enzymes, and vitamins. The claim that fosphenytoin carries the same propylene glycol vehicle as phenytoin is factually wrong — fosphenytoin is water-soluble and specifically formulated to avoid propylene glycol, which is the source of phenytoin's infusion-site and cardiac toxicities.
Option C: Option C is incorrect. Fosphenytoin is not dosed in milligrams of elemental phenytoin per se — it uses the PE designation to make the equivalence explicit and standardized. More critically, the infusion rates are not identical: fosphenytoin can be infused at up to 150 mg PE/min versus 50 mg/min for phenytoin. Describing fosphenytoin as merely a more soluble salt form misrepresents its prodrug pharmacology — it must be hydrolyzed by plasma phosphatases to phenytoin before any channel-blocking activity occurs.
Option D: Option D is incorrect. Fosphenytoin dosing is not weight-based in millimoles per kilogram; it uses the fixed PE unit system for simplicity and safety in clinical practice. Weight-based millimolar dosing would introduce calculation steps in emergency settings and is not consistent with any established fosphenytoin prescribing standard. The PE system was designed precisely to eliminate complex weight-normalized conversions.
4. What is the molecular mechanism and clinical time course of carbamazepine autoinduction, and what are the pharmacokinetic consequences for dosing?
A) Carbamazepine autoinduction occurs through competitive inhibition of CYP2C9 by carbamazepine-10,11-epoxide (CBZ-E), which accumulates over the first 72 hours of therapy and then blocks further carbamazepine metabolism; clinically, this produces a paradoxical rise in carbamazepine concentrations after day 3 requiring immediate dose reduction
B) Carbamazepine activates the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), upregulating transcription of CYP3A4 — the enzyme primarily responsible for carbamazepine's own metabolism — over 2–4 weeks of continued dosing; the half-life shortens from approximately 25–65 hours at initiation to 12–17 hours at steady state, requiring upward dose titration as induction stabilizes
C) Carbamazepine autoinduction occurs through post-translational modification of CYP1A2 by the carbamazepine N-oxide metabolite, which becomes maximally active within 48 hours of initiation; this produces a predictable 50% reduction in carbamazepine half-life within the first week, allowing rapid dose stabilization
D) Carbamazepine is a substrate and irreversible inhibitor of CYP3A4; at low doses early in therapy, CYP3A4 is partially inhibited, prolonging the half-life; at higher therapeutic doses, the enzyme is fully inhibited, producing zero-order kinetics analogous to phenytoin's saturation kinetics
E) Carbamazepine autoinduction is mediated by P-glycoprotein upregulation in the intestinal wall, which reduces oral bioavailability from approximately 85% at initiation to approximately 30% at steady state over the first 4 weeks of therapy, explaining the decline in plasma concentrations at a fixed dose
ANSWER: B
Rationale:
Option B is correct. Carbamazepine induces its own metabolism through activation of nuclear receptors — primarily the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) — which upregulate the transcription of CYP3A4, the cytochrome P450 enzyme primarily responsible for carbamazepine's hepatic metabolism. New CYP3A4 protein must be synthesized and accumulate in hepatocytes, a process that takes 2–4 weeks to reach a new steady state. During this time, carbamazepine clearance increases progressively, shortening the half-life from approximately 25–65 hours at the start of therapy (before induction is established) to 12–17 hours at pharmacokinetic steady state once autoinduction is complete. The clinical consequence is that plasma concentrations at a fixed daily dose will fall over the first 2–4 weeks of therapy — concentrations measured at week 1 will be substantially higher than those measured at week 4 at the same dose. Initiation must therefore begin at a low dose to avoid toxicity before autoinduction, followed by upward titration as autoinduction stabilizes.
Option A: Option A is incorrect. Carbamazepine autoinduction is not mediated by CBZ-E inhibition of CYP2C9. CYP2C9 is not the primary enzyme for carbamazepine metabolism, and CBZ-E does not accumulate and inhibit further carbamazepine clearance. The described pattern — a paradoxical rise in concentration after day 3 requiring dose reduction — is the opposite of what occurs. Autoinduction increases carbamazepine clearance, causing concentrations to fall over weeks, not rise acutely within days.
Option C: Option C is incorrect. CYP1A2 is not the relevant autoinduction target for carbamazepine, and the carbamazepine N-oxide metabolite is not the mediator of this effect. Autoinduction primarily involves CYP3A4 transcriptional upregulation via PXR and CAR activation. The time course described — maximal effect within 48 hours — is far too rapid; autoinduction develops over 2–4 weeks as new enzyme protein is synthesized, not within two days.
Option D: Option D is incorrect. Carbamazepine is not an irreversible CYP3A4 inhibitor. It is a CYP3A4 inducer. Describing it as producing CYP3A4 inhibition that transitions to saturation kinetics analogous to phenytoin conflates two entirely different pharmacokinetic mechanisms. Carbamazepine's clinical complexity arises from autoinduction increasing clearance over time, not from enzyme inhibition or saturation.
Option E: Option E is incorrect. Carbamazepine autoinduction is primarily a hepatic, not an intestinal, phenomenon. P-glycoprotein upregulation in the intestinal wall is not the established mechanism of carbamazepine autoinduction, and bioavailability does not decline from 85% to 30% over the first month. Carbamazepine's oral bioavailability remains in the 75–85% range at steady state; the falling plasma concentrations at a fixed dose reflect increased hepatic CYP3A4-mediated clearance, not reduced intestinal absorption.
5. What is the voltage-dependent basis of state-dependent blockade by phenytoin and carbamazepine, and how does this explain their selectivity for ictal over normal neuronal firing?
A) At hyperpolarized resting membrane potentials, sodium channels are predominantly in the open state; phenytoin and carbamazepine preferentially bind open channels, producing greater blockade at rest than during high-frequency firing — a paradoxical mechanism that works because resting blockade lowers the threshold for seizure termination
B) Phenytoin and carbamazepine bind with equal affinity to resting, open, and inactivated sodium channel states; selectivity for ictal neurons arises solely from the higher intracellular drug concentration achieved in neurons that fire frequently, because repeated depolarization drives drug influx through open channels
C) Phenytoin and carbamazepine bind only to channels in the resting state; during ictal firing, rapid cycling between resting and open states increases the fraction of time channels spend in the resting state, producing greater cumulative block during seizure activity than during normal tonic firing
D) At the depolarized membrane potentials maintained during ictal burst firing, a greater proportion of Nav channels occupy the fast-inactivated state; phenytoin and carbamazepine bind with high affinity to the inactivated state and dissociate slowly, slowing recovery to the resting (available) state and selectively suppressing high-frequency epileptic firing over normal physiological activity
E) Phenytoin and carbamazepine are voltage-independent blockers that act by reducing the total number of functional Nav channels expressed at the neuronal membrane; their selectivity for ictal firing arises because epileptic neurons depend more heavily on Nav channel availability than do tonically firing normal neurons
ANSWER: D
Rationale:
Option D is correct. The selectivity of phenytoin and carbamazepine for epileptic over normal neuronal firing depends on the voltage-dependent distribution of Nav channels among their functional states. At normal resting membrane potentials (approximately −70 mV), the vast majority of Nav channels occupy the resting (closed but available) state, to which phenytoin and carbamazepine bind with low affinity and from which they dissociate rapidly. During ictal high-frequency burst firing, neurons sustain prolonged membrane depolarization; at depolarized potentials, a substantially greater fraction of channels occupy the fast-inactivated state (the IFM-gated conformation produced within milliseconds of channel opening). Phenytoin and carbamazepine bind this inactivated state with high affinity, and drug-bound inactivated channels recover to the available resting state more slowly than unoccupied channels. The combination of high affinity binding at depolarized potentials and slow recovery produces frequency-dependent accumulation of block — channels available for the next action potential in an ictal burst are progressively fewer, selectively suppressing high-frequency epileptic firing. At normal physiological firing rates, rapid recovery between action potentials ensures that block does not accumulate to the same degree.
Option A: Option A is incorrect. The premise is inverted. At resting (hyperpolarized) membrane potentials, channels are in the resting state, not the open state, and drug binding affinity is low. The open state is a transient conformation lasting only fractions of a millisecond during each action potential. The selectivity mechanism relies on preferential binding to the inactivated state at depolarized potentials — not on binding open channels at rest. The described mechanism does not correspond to any established pharmacology of sodium channel anti-seizure drugs.
Option B: Option B is incorrect. Phenytoin and carbamazepine do not bind all channel states with equal affinity. Their defining pharmacological property is state-dependent selectivity — markedly higher affinity for the inactivated state than for the resting state. If binding were state-independent, the drugs would produce concentration-dependent suppression of all neuronal activity without a therapeutic window, which contradicts their established clinical profile. Drug accumulation driven by repeated depolarization opening channels is a real phenomenon (use dependence) but operates on top of state selectivity, not as a replacement for it.
Option C: Option C is incorrect. Phenytoin and carbamazepine do not bind only to the resting state. The opposite is true: they bind the inactivated state with high affinity and the resting state weakly. The described mechanism — greater block during seizures because channels spend more time in the resting state — is pharmacologically inverted. During seizures, channels spend more time in the inactivated state (not the resting state), and it is the inactivated state that accumulates drug.
Option E: Option E is incorrect. Phenytoin and carbamazepine are not voltage-independent blockers that reduce Nav channel expression. They exert acute pharmacological effects on channel gating kinetics — specifically by stabilizing the inactivated conformation — not by reducing channel synthesis or membrane insertion. Changes in Nav channel expression occur over much longer timescales (hours to days) through transcriptional regulation and are not the mechanism of acute antiseizure activity.
6. What is the active metabolite of oxcarbazepine, by what enzymatic mechanism is it produced, and what pharmacokinetic advantage does this pathway confer compared to carbamazepine?
A) The active metabolite of oxcarbazepine is carbamazepine-10,11-epoxide (CBZ-E), produced by CYP3A4-mediated epoxidation; because CBZ-E has a longer half-life than the parent compound, oxcarbazepine provides more sustained Nav channel blockade than carbamazepine at equivalent doses
B) Oxcarbazepine has no active metabolite; it acts directly as the parent compound and is eliminated unchanged by renal excretion; this absence of hepatic metabolism accounts for its lower drug interaction burden compared to carbamazepine
C) The active metabolite of oxcarbazepine is the monohydroxy derivative (MHD, also called licarbazepine), produced by hepatic cytosolic ketoreduction; because this pathway does not generate a 10,11-epoxide intermediate, CBZ-E toxicity is eliminated — a key pharmacokinetic advantage over carbamazepine
D) The active metabolite of oxcarbazepine is an N-glucuronide conjugate produced by UGT2B7; glucuronidation at the nitrogen produces a water-soluble metabolite with full Nav channel-blocking activity and a half-life of approximately 40 hours, suitable for once-daily dosing
E) Oxcarbazepine is converted to its active metabolite by intestinal esterases during first-pass absorption; the metabolite reaches the systemic circulation before the liver is exposed to any parent compound, which is why hepatic CYP enzyme interactions do not reduce the bioavailability of the active species
ANSWER: C
Rationale:
Option C is correct. Oxcarbazepine is a prodrug that is rapidly and essentially completely reduced by hepatic cytosolic ketoreductase enzymes to its active monohydroxy derivative (MHD), also called licarbazepine (a mixture of R- and S-enantiomers). MHD is the pharmacologically active species responsible for Nav channel blockade. The key distinction from carbamazepine is the enzymatic pathway: carbamazepine is oxidized by CYP3A4 to carbamazepine-10,11-epoxide (CBZ-E), an active and potentially toxic metabolite; oxcarbazepine's ketoreduction pathway bypasses CYP3A4-mediated epoxidation entirely, so the 10,11-epoxide is never generated. This eliminates CBZ-E-related toxicities — particularly the diplopia, dizziness, and nausea that can occur at apparently therapeutic carbamazepine concentrations when CBZ-E accumulates (e.g., when co-administered with valproate, which inhibits epoxide hydrolase). MHD has a half-life of approximately 9–11 hours and is eliminated predominantly by UGT glucuronidation. Oxcarbazepine also does not undergo meaningful autoinduction of its own metabolism, in contrast to carbamazepine.
Option A: Option A is incorrect. CBZ-E is the active epoxide metabolite of carbamazepine, not of oxcarbazepine. The entire pharmacokinetic rationale for oxcarbazepine's development was to avoid CBZ-E formation by using a ketoreduction pathway instead of CYP3A4-mediated epoxidation. Stating that oxcarbazepine produces CBZ-E reverses the foundational metabolic distinction between these two drugs.
Option B: Option B is incorrect. Oxcarbazepine does have a clinically important active metabolite (MHD) and does not act primarily as the parent compound; it is essentially a prodrug. It is not eliminated unchanged by renal excretion. While MHD has a lower interaction burden than carbamazepine due to weaker CYP3A4 induction, the characterization of oxcarbazepine as a renally excreted, non-metabolized drug is entirely incorrect.
Option D: Option D is incorrect. N-glucuronidation by UGT2B7 is not the metabolic pathway that produces oxcarbazepine's active species. Glucuronidation by UGT enzymes is the primary elimination route for MHD after it is formed, but the conversion of oxcarbazepine to MHD is through cytosolic ketoreduction, not glucuronidation. An N-glucuronide with full Nav channel activity and a 40-hour half-life is not a pharmacologically established species in oxcarbazepine metabolism.
Option E: Option E is incorrect. Oxcarbazepine's conversion to MHD is primarily a hepatic process, not an intestinal esterase reaction. The liver is absolutely involved in prodrug activation. Describing intestinal esterases as the primary site of conversion misrepresents the metabolic biology of oxcarbazepine and would imply a mechanism similar to aspirin hydrolysis by gut esterases — which is not the case for oxcarbazepine's ketoreduction.
7. What fraction of phenytoin is bound to plasma albumin, what is the clinical significance of this binding in patients with hypoalbuminemia, and what approach corrects for the distortion in total drug concentration measurement?
A) Phenytoin is approximately 90% bound to albumin; in hypoalbuminemic patients, the unbound (free) fraction is higher than in normal subjects, so a measured total concentration may appear subtherapeutic or therapeutic while the pharmacologically active free concentration is already at or above the toxic range; the Sheiner-Tozer formula or direct free phenytoin measurement corrects for this distortion
B) Phenytoin is approximately 40% bound to albumin, with the remainder bound to alpha-1-acid glycoprotein; hypoalbuminemia does not substantially affect free phenytoin fraction because alpha-1-acid glycoprotein binding is maintained; no correction formula is needed
C) Phenytoin is approximately 90% bound to albumin; in hypoalbuminemia, however, the liver compensates by increasing CYP2C9 expression to maintain normal free phenytoin concentrations; total plasma concentration falls in parallel with the free fraction, so standard total concentration measurements remain interpretable without correction
D) Phenytoin is essentially 100% protein-bound under normal conditions; the free fraction is negligible and cannot cross the blood-brain barrier; hypoalbuminemia paradoxically reduces phenytoin's antiseizure efficacy by increasing drug-albumin dissociation and promoting renal excretion of the free compound
E) Phenytoin is approximately 70% bound to albumin, with the binding saturable within the therapeutic range; as total concentration rises above 15 mg/L, protein binding becomes saturated and the free fraction increases nonlinearly, creating a toxicity threshold that is independent of the patient's albumin level
ANSWER: A
Rationale:
Option A is correct. Phenytoin is approximately 90% bound to plasma albumin under normal conditions, leaving approximately 10% as the free (unbound) fraction. Only the free fraction is pharmacologically active, capable of crossing the blood-brain barrier, and responsible for both therapeutic effects and toxicity. In patients with hypoalbuminemia — which occurs in liver disease, nephrotic syndrome, malnutrition, critical illness, pregnancy, and advanced age — albumin binding sites are reduced, the free fraction increases substantially above 10%, and the relationship between total measured plasma concentration and pharmacological effect is distorted. A total phenytoin concentration that appears subtherapeutic (e.g., 8 mg/L) may correspond to a free concentration that is already at or above the therapeutic range of approximately 1–2 mg/L, making dose escalation based on total concentration hazardous. The Sheiner-Tozer formula estimates the corrected total phenytoin concentration that would correspond to the measured total concentration in a patient with normal albumin; alternatively, direct measurement of free phenytoin concentration is the most reliable approach.
Option B: Option B is incorrect. Phenytoin is not 40% albumin-bound; it is approximately 90% albumin-bound. Alpha-1-acid glycoprotein is a binding protein relevant for basic drugs (e.g., lidocaine, propranolol), not for phenytoin, which is an acidic drug with high albumin affinity. The claim that hypoalbuminemia does not affect the free phenytoin fraction is incorrect and clinically dangerous — it would lead to under-recognition of elevated free concentrations in high-risk patients.
Option C: Option C is incorrect. The liver does not compensate for hypoalbuminemia by upregulating CYP2C9 to maintain free phenytoin concentrations. Hepatic enzyme regulation and plasma protein binding are distinct processes with different regulatory mechanisms. In hypoalbuminemia, total phenytoin concentrations fall (because there are fewer binding sites to carry drug in the protein-bound form) while free concentrations are disproportionately elevated — the opposite of a compensated normal free fraction. Standard total concentration measurements are unreliable in hypoalbuminemic patients and require correction.
Option D: Option D is incorrect. Phenytoin is not essentially 100% protein-bound; its free fraction is approximately 10% under normal conditions and is the clinically active species. The premise that phenytoin cannot cross the blood-brain barrier is contradicted by its established antiseizure efficacy — the free fraction does cross the blood-brain barrier and produces all therapeutic and toxic CNS effects. Hypoalbuminemia increases, not decreases, free phenytoin concentration and clinical effect.
Option E: Option E is incorrect. Phenytoin protein binding is approximately 90% and is not saturable within the therapeutic range by protein binding. The nonlinear plasma concentration behavior of phenytoin arises from enzyme saturation (Michaelis-Menten kinetics of CYP2C9), not from saturation of albumin binding sites. Albumin has abundant binding capacity for phenytoin at therapeutic concentrations; protein binding saturation is not a recognized pharmacokinetic mechanism for phenytoin toxicity.
8. What is the pharmacokinetic relationship between the intravenous and oral formulations of lacosamide, and what is lacosamide's established clinical role in the management of status epilepticus?
A) The intravenous formulation of lacosamide has approximately 60% bioavailability relative to oral dosing because the prodrug conversion from the IV ester to active lacosamide requires hepatic first-pass metabolism that is bypassed when the drug is given orally
B) Intravenous lacosamide achieves twice the peak plasma concentration of the oral formulation at the same nominal dose; IV dosing is therefore typically given at half the oral dose to maintain equivalent plasma exposure when transitioning between routes
C) Lacosamide has no established role in status epilepticus because its slow inactivation mechanism requires hours of sustained membrane depolarization to accumulate sufficient channel block; it is used only for maintenance therapy in outpatients with focal epilepsy
D) Intravenous lacosamide is the first-line second-stage agent for convulsive status epilepticus, having demonstrated superior efficacy to fosphenytoin, valproate, and levetiracetam in the Emergency Treatment with Levetiracetam, Fosphenytoin, or Valproate (ESETT) trial; its PR-prolonging effect is a known limitation in this setting
E) The intravenous formulation of lacosamide is bioequivalent to the oral formulation and can be given at the same doses, making it practical for hospitalized patients unable to take oral medications; lacosamide has not been evaluated as a primary agent in a randomized controlled trial for status epilepticus comparable to the ESETT trial, but is used clinically when first-line second-stage agents have failed or are contraindicated
ANSWER: E
Rationale:
Option E is correct. Lacosamide's intravenous formulation is bioequivalent to its oral formulation — the same dose produces the same systemic exposure by either route — because lacosamide's oral bioavailability is approximately 100%. This 1:1 equivalence is a clinically significant advantage: when a patient who was stable on oral lacosamide requires hospital admission and cannot take oral medications, the IV formulation can be substituted at exactly the same total daily dose and dosing interval without any pharmacokinetic dose conversion. Regarding status epilepticus (SE), lacosamide has not yet been evaluated as a primary second-stage agent in a randomized controlled trial with the statistical power of the ESETT trial. The ESETT trial (Emergency Treatment with Levetiracetam, Fosphenytoin, or Valproate) compared these three agents as second-line therapy for benzodiazepine-refractory convulsive SE and demonstrated equivalent efficacy across the three arms. Lacosamide was not included in ESETT; its use in SE is supported by retrospective and observational data and is employed when fosphenytoin, valproate, or levetiracetam have failed or are contraindicated.
Option A: Option A is incorrect. Lacosamide is not a prodrug when given intravenously — it is administered directly as the active drug. Its approximately 100% oral bioavailability means there is no meaningful first-pass metabolism to bypass; both routes deliver essentially equivalent systemic exposure. The 60% IV-to-oral bioavailability ratio described does not exist for lacosamide.
Option B: Option B is incorrect. The IV and oral formulations of lacosamide are bioequivalent, not in a 2:1 peak concentration ratio. Because oral bioavailability is nearly 100%, IV dosing does not produce double the plasma concentration of equivalent oral dosing. Halving the IV dose when switching from oral would result in subtherapeutic lacosamide exposure and is not consistent with prescribing standards.
Option C: Option C is incorrect. Lacosamide's slow inactivation mechanism does not require hours of sustained depolarization to be clinically active. Slow inactivation is engaged during the prolonged depolarization of ictal discharges (hundreds of milliseconds to seconds) — not over hours. More importantly, lacosamide does have an established and growing clinical role in acute seizure management including status epilepticus, albeit based on observational rather than phase III randomized trial data as of current evidence.
Option D: Option D is incorrect. Lacosamide was not evaluated in the ESETT trial, and it was not demonstrated to be superior to fosphenytoin, valproate, or levetiracetam in that trial. The ESETT trial showed equivalence among those three agents as second-line SE treatment. Describing lacosamide as the first-line second-stage agent based on ESETT results is factually wrong — lacosamide was not an ESETT study drug.
9. What is carbamazepine-10,11-epoxide (CBZ-E), by what pathway is it formed and eliminated, and why does co-administration of valproate cause CBZ-E accumulation without raising the measured carbamazepine concentration?
A) CBZ-E is an inactive phase II glucuronide conjugate formed by UGT1A4; it accumulates in renal failure because it is eliminated exclusively by glomerular filtration; valproate raises CBZ-E concentrations by inhibiting UGT1A4 and diverting carbamazepine metabolism toward an alternative hydroxylation pathway that also produces CBZ-E
B) CBZ-E is an active metabolite of carbamazepine produced by CYP3A4-mediated 10,11-epoxidation of the dibenzazepine ring; it is converted to an inactive trans-diol by epoxide hydrolase; valproate inhibits epoxide hydrolase, causing CBZ-E to accumulate at apparently therapeutic parent carbamazepine concentrations because standard carbamazepine TDM measures parent drug only, not CBZ-E
C) CBZ-E is a reactive intermediate produced during CYP2C9-mediated metabolism of carbamazepine; it is rapidly detoxified by glutathione S-transferase in the liver; valproate depletes hepatic glutathione, allowing CBZ-E to escape detoxification and accumulate in plasma
D) CBZ-E is the primary pharmacologically active species of carbamazepine; the parent drug is a prodrug with no intrinsic Nav channel-blocking activity; valproate raises CBZ-E concentrations by inhibiting CYP3A4, which paradoxically reduces carbamazepine conversion to an inactive downstream metabolite and allows more drug to proceed through the epoxidation pathway
E) CBZ-E has no clinical significance and does not contribute to carbamazepine's therapeutic effect or adverse effects; it is a minor metabolite present at negligible concentrations that is eliminated within minutes by spontaneous hydrolysis at physiological pH
ANSWER: B
Rationale:
Option B is correct. Carbamazepine undergoes CYP3A4-mediated oxidation of the 10,11 double bond in its dibenzazepine ring to form carbamazepine-10,11-epoxide (CBZ-E), an active metabolite that contributes meaningfully to both the therapeutic and adverse effects of the parent drug. Under normal circumstances, CBZ-E is rapidly converted to the pharmacologically inert carbamazepine-10,11-trans-diol by the enzyme epoxide hydrolase. Valproate is a potent inhibitor of epoxide hydrolase. When valproate is added to carbamazepine therapy, epoxide hydrolase activity is reduced and CBZ-E clearance slows substantially, causing CBZ-E plasma concentrations to rise. The critical clinical feature is that standard therapeutic drug monitoring (TDM) for carbamazepine measures only parent carbamazepine concentration, not CBZ-E. A patient on carbamazepine with a stable parent drug concentration who develops toxicity symptoms (diplopia, dizziness, nausea, ataxia) after starting valproate may have normal or even slightly reduced carbamazepine levels — the toxicity is driven by accumulating CBZ-E that is invisible to routine monitoring. When this pattern is suspected, direct measurement of CBZ-E concentration is diagnostically informative.
Option A: Option A is incorrect. CBZ-E is not a phase II glucuronide conjugate and is not formed by UGT1A4. It is a phase I oxidative metabolite formed by CYP3A4-mediated epoxidation — a reactive intermediate rather than a conjugated species. CBZ-E is not eliminated exclusively by renal filtration; it is converted hepatically to the trans-diol by epoxide hydrolase. Valproate's interaction involves epoxide hydrolase inhibition, not UGT1A4 inhibition.
Option C: Option C is incorrect. CYP2C9 is not the primary enzyme responsible for CBZ-E formation — CYP3A4 is. The detoxification of CBZ-E is performed by epoxide hydrolase, not glutathione S-transferase. While glutathione conjugation is an important detoxification pathway for some epoxide intermediates (particularly those formed from aromatic hydrocarbons), it is not the established pathway for CBZ-E metabolism. Valproate does not accumulate to concentrations that deplete hepatic glutathione under therapeutic conditions.
Option D: Option D is incorrect. Carbamazepine is not a prodrug requiring conversion to CBZ-E for pharmacological activity; the parent compound itself is the primary Nav channel-blocking agent, and CBZ-E contributes additional activity. Valproate's interaction with carbamazepine is through epoxide hydrolase inhibition slowing CBZ-E degradation — not through CYP3A4 inhibition redirecting metabolism toward epoxidation.
Option E: Option E is incorrect. CBZ-E is not a clinically insignificant minor metabolite. It accumulates to substantial plasma concentrations (typically 10–30% of parent carbamazepine concentrations) under normal conditions, and this fraction rises further with epoxide hydrolase inhibitors such as valproate. CBZ-E contributes to both the antiseizure efficacy and the dose-related adverse effects of carbamazepine therapy; it does not undergo spontaneous hydrolysis at physiological pH and is not eliminated within minutes.
10. For which patient population is HLA-B*1502 genotyping required before initiating carbamazepine, which other anti-seizure drugs carry the same screening requirement due to shared risk, and what severe adverse reaction does the allele predict?
A) HLA-B*1502 screening is required in all patients regardless of ancestry before initiating any aromatic anti-seizure drug; the allele predicts drug reaction with eosinophilia and systemic symptoms (DRESS), which manifests as fever, lymphadenopathy, and organ dysfunction 2–8 weeks after drug initiation
B) HLA-B*1502 screening is required in patients of Northern European ancestry before initiating carbamazepine; the allele predicts a risk of drug-induced lupus erythematosus; phenytoin does not carry the same requirement because it lacks the aromatic dibenzazepine ring structure that triggers immune recognition in HLA-B*1502 carriers
C) HLA-B*1502 screening is required before initiating lacosamide and levetiracetam in all patients; it predicts a risk of severe PR interval prolongation and complete atrioventricular block that is pharmacogenomically determined rather than dose-dependent
D) HLA-B*1502 screening is required in patients of Southeast Asian ancestry before initiating carbamazepine, phenytoin, or oxcarbazepine; the allele confers an extremely high risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with these aromatic anti-seizure drugs; a patient who has experienced a severe cutaneous adverse reaction to one aromatic agent should not receive another without specialist consultation
E) HLA-B*1502 screening is required only in patients of Han Chinese ancestry before initiating carbamazepine; phenytoin and oxcarbazepine do not require screening because their hepatic metabolites do not share the reactive epoxide intermediate implicated in the immune-mediated cutaneous reaction
ANSWER: D
Rationale:
Option D is correct. HLA-B*1502 is an allele with markedly elevated prevalence in populations of Southeast Asian ancestry — including Han Chinese, Thai, Malaysian, Philippine, and Vietnamese patients — in whom it is present in 5–10% of individuals, compared to less than 1% in European populations. Carriers of HLA-B*1502 face an extremely high risk (estimated 25-fold or greater above background) of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine; these life-threatening severe cutaneous adverse reactions (SCARs) involve widespread epidermal detachment and carry significant mortality. Regulatory agencies including the FDA and international equivalents require screening of patients of Southeast Asian ancestry for HLA-B*1502 before initiating carbamazepine. The cross-reactivity extends to phenytoin and oxcarbazepine, which share structural similarity and are also associated with SCAR risk in HLA-B*1502 carriers; these agents should be avoided in screen-positive patients. Because SCARs to aromatic anti-seizure drugs (carbamazepine, phenytoin, phenobarbital, oxcarbazepine) share immunological mechanisms, a patient who has experienced a SCAR to one agent in this class should not receive another without specialist input.
Option A: Option A is incorrect. HLA-B*1502 screening is not required in all patients regardless of ancestry; it is specifically mandated for patients of Southeast Asian ancestry, in whom the allele prevalence is clinically significant. Universal screening of all patients is not the regulatory standard. Additionally, the adverse reaction predicted by HLA-B*1502 is SJS/TEN (epidermal necrosis and detachment), not DRESS (which has distinct clinical features and is associated with different HLA alleles, including HLA-A*3101 for carbamazepine-related DRESS in European and Japanese populations).
Option B: Option B is incorrect. HLA-B*1502 is not a Northern European ancestry allele; it is highly prevalent in Southeast Asian populations. The adverse reaction predicted is SJS/TEN, not drug-induced lupus. Phenytoin does carry an HLA-B*1502-associated SCAR risk due to its aromatic structure and shares the screening requirement for Southeast Asian patients; it should not be excluded from the cross-reactivity risk.
Option C: Option C is incorrect. HLA-B*1502 has no established association with lacosamide or levetiracetam, and neither drug carries an HLA-B*1502-based screening requirement. Lacosamide's cardiac PR interval prolongation is a pharmacodynamic, dose-dependent effect — not a pharmacogenomic immune-mediated reaction. The HLA-B*1502 risk is specific to structurally aromatic anti-seizure drugs (carbamazepine, phenytoin, oxcarbazepine, phenobarbital).
Option E: Option E is incorrect. While Han Chinese patients are the population in whom the HLA-B*1502 risk was first and most extensively studied, the screening requirement applies more broadly to all patients of Southeast Asian ancestry, not exclusively Han Chinese. Furthermore, phenytoin and oxcarbazepine do share the SCAR risk in HLA-B*1502 carriers and do require the same precaution — the claim that they are exempt because of differences in reactive metabolites is not consistent with established pharmacogenomic guidelines or clinical evidence.
11. How does lacosamide's binding site on the Nav channel alpha subunit differ from that of phenytoin and carbamazepine, what inactivation state does lacosamide preferentially stabilize, and what is the pharmacological consequence when lacosamide is combined with a classical fast-inactivation enhancer?
A) Lacosamide binds the same local anesthetic site as phenytoin and carbamazepine but with greater affinity; when combined with carbamazepine, competitive displacement at the shared binding site produces a pharmacokinetic interaction that reduces plasma concentrations of both drugs by approximately 30%
B) Lacosamide binds the extracellular P-loop selectivity filter and stabilizes the closed (resting) state; when combined with fast-inactivation enhancers such as phenytoin, lacosamide's resting-state stabilization opposes phenytoin's inactivation-state effects, producing pharmacological antagonism that reduces overall sodium channel blockade
C) Lacosamide binds a site on the Nav channel alpha subunit distinct from the local anesthetic binding site used by phenytoin and carbamazepine; it selectively stabilizes the slow-inactivated state without affecting fast inactivation; when combined with a classical fast-inactivation enhancer, the effects are additive because the two drugs act on pharmacologically distinct conformational states
D) Lacosamide binds the same local anesthetic site as phenytoin but on a different domain interface — specifically the DIII–DIV linker — which happens to overlap with the IFM inactivation gate; this structural overlap means lacosamide simultaneously enhances both fast and slow inactivation, making it the most potent state-dependent blocker in the class
E) Lacosamide has no direct binding site on the Nav channel; it acts by inhibiting collapsin response mediator protein-2 (CRMP-2), an intracellular scaffolding protein that transports Nav channels to the neuronal membrane; reduced channel membrane insertion lowers total available Nav channel density in actively firing neurons
ANSWER: C
Rationale:
Option C is correct. Lacosamide's mechanism of action is mechanistically distinct from all classical sodium channel anti-seizure drugs. Phenytoin, carbamazepine, oxcarbazepine, lamotrigine, and zonisamide all bind the local anesthetic binding site on the Nav channel alpha subunit — a hydrophobic pocket accessible from the intracellular side of the channel pore, located within or near the S6 segments. Lacosamide binds a different site on the alpha subunit, and through this distinct interaction it preferentially stabilizes the slow-inactivated state of the Nav channel without materially affecting fast inactivation gating or the local anesthetic binding site. Slow inactivation is a distinct conformational state from fast inactivation: it develops over hundreds of milliseconds to seconds of sustained membrane depolarization, involves rearrangements in the pore-lining S6 segments rather than IFM gate occlusion, and recovers much more slowly. Because lacosamide and classical agents act on different Nav channel conformational states through different binding sites, their effects are pharmacologically additive rather than redundant when combined — providing the mechanistic rationale for using lacosamide as an adjunct to carbamazepine or other classical agents in drug-resistant focal epilepsy.
Option A: Option A is incorrect. Lacosamide does not share the local anesthetic binding site with phenytoin and carbamazepine. If it did, their mechanisms would be redundant rather than complementary, and no additional seizure control would be expected from combining lacosamide with a classical sodium channel blocker — which contradicts clinical evidence. There is no established pharmacokinetic interaction in which lacosamide displaces carbamazepine from a shared binding site to reduce plasma concentrations of both drugs.
Option B: Option B is incorrect. Lacosamide does not bind the P-loop selectivity filter and does not stabilize the resting state. Binding the selectivity filter would be expected to block ion conduction regardless of channel state — a very different mechanism from state-dependent blockade. There is no pharmacological antagonism between lacosamide and fast-inactivation enhancers; the clinical rationale for combining lacosamide with classical agents is precisely because their mechanisms are additive, not antagonistic.
Option D: Option D is incorrect. Lacosamide does not bind the DIII–DIV linker, which is where the IFM inactivation gate is located; that region is the binding domain of no known clinically used ASD. The claim that lacosamide enhances both fast and slow inactivation simultaneously contradicts its established mechanistic profile. Lacosamide's defining pharmacological property is selective slow inactivation enhancement without affecting fast inactivation — this selectivity is what makes it mechanistically complementary to classical fast-inactivation enhancers.
Option E: Option E is incorrect. While lacosamide does have a reported interaction with CRMP-2 (collapsin response mediator protein-2) in preclinical studies, the primary established mechanism of its antiseizure action is direct binding to the Nav channel alpha subunit and selective enhancement of slow inactivation. The CRMP-2 interaction is of uncertain clinical relevance and is not the accepted pharmacological basis for lacosamide's antiseizure efficacy. Nav channel membrane insertion reduction via CRMP-2 is not the mechanistic explanation used in clinical pharmacology.
12. What are the established therapeutic concentration ranges for total and free phenytoin, when should TDM samples be drawn to obtain a valid trough measurement, and why does phenytoin's kinetic behavior extend the time required to reach steady state compared to a first-order drug?
A) The therapeutic range for total phenytoin is 10–20 mg/L, corresponding to a free phenytoin range of approximately 1–2 mg/L; trough samples should be drawn just before the next scheduled dose after steady state has been reached; because phenytoin's half-life lengthens as plasma concentration rises toward and above the saturation threshold (Michaelis-Menten kinetics), steady state may take longer to achieve after a dose increase than predicted from a simple five-half-life calculation
B) The therapeutic range for total phenytoin is 5–10 mg/L, corresponding to a free range of 2–4 mg/L; peak samples drawn 2–4 hours after the oral dose are preferred because the peak better predicts efficacy, and steady state is typically reached within 24 hours because phenytoin has rapid first-order kinetics at all therapeutic concentrations
C) The therapeutic range for total phenytoin is 20–40 mg/L, corresponding to a free range of 4–8 mg/L; trough sampling is not meaningful because phenytoin redistributes from plasma to brain tissue within minutes of each dose, making plasma concentration an unreliable surrogate for CNS drug levels
D) Total and free phenytoin therapeutic ranges are interchangeable and both expressed as 10–20 mg/L because protein binding is negligible at clinical doses; steady state is achieved within two to three days regardless of dose because phenytoin's half-life is fixed at 24 hours by its rate of CYP2C9-mediated glucuronidation
E) The therapeutic range for total phenytoin is 10–20 mg/L; there is no clinically accepted free phenytoin therapeutic range because free phenytoin assays are not standardized across clinical laboratories; TDM samples may be drawn at any time during the dosing interval because phenytoin's long half-life produces a flat concentration-time profile with negligible peak-to-trough variation
ANSWER: A
Rationale:
Option A is correct. The conventional therapeutic range for total phenytoin is 10–20 mg/L (40–79 micromol/L), and the corresponding free phenytoin therapeutic range is approximately 1–2 mg/L (reflecting the ~10% free fraction under normal protein binding conditions). Trough samples — drawn just before the next scheduled dose — are the standard sampling time for phenytoin TDM because they represent the minimum concentration in the dosing interval and provide a reproducible comparison point across visits. An important nuance specific to phenytoin's kinetics: because phenytoin follows Michaelis-Menten (zero-order) kinetics above the enzyme saturation threshold (~5–10 mg/L), the apparent half-life is not fixed but lengthens as concentration increases. At concentrations approaching and exceeding saturation, the rate of elimination no longer increases proportionally with concentration, so the time to reach steady state after a dose increase can exceed the standard five-half-life estimate. Clinicians must allow adequate time — at minimum two to three weeks — between dose changes before re-measuring trough concentrations to ensure steady state has been achieved.
Option B: Option B is incorrect. The correct therapeutic range for total phenytoin is 10–20 mg/L, not 5–10 mg/L. A range of 5–10 mg/L is near the enzyme saturation threshold — below the therapeutic target for most patients — and would lead to systematic under-treatment. Peak sampling 2–4 hours post-dose is not the standard for phenytoin monitoring; trough sampling is preferred. Phenytoin does not exhibit rapid first-order kinetics at all therapeutic concentrations; it has nonlinear saturation kinetics above 5–10 mg/L.
Option C: Option C is incorrect. The therapeutic range of 20–40 mg/L is frankly supratherapeutic; nystagmus typically appears above 20 mg/L, ataxia above 30 mg/L, and lethargy above 40 mg/L. A free range of 4–8 mg/L would be several times above the therapeutic free fraction. Plasma phenytoin concentration is a well-validated surrogate for CNS drug levels — it does not redistribute rapidly away from plasma in a manner that makes monitoring unreliable.
Option D: Option D is incorrect. Total and free phenytoin therapeutic ranges are not expressed in the same units or as interchangeable values. The protein binding is approximately 90%, not negligible, and the free fraction is clinically critical — particularly in hypoalbuminemic patients. Phenytoin's half-life is not fixed at 24 hours and is not determined by glucuronidation; it is metabolized primarily by CYP2C9-mediated hydroxylation and has a variable, concentration-dependent half-life of 22–36 hours at therapeutic concentrations.
Option E: Option E is incorrect. Free phenytoin assays are clinically standardized and widely used; a free phenytoin therapeutic range of approximately 1–2 mg/L is accepted in clinical pharmacology practice. More importantly, the claim that samples can be drawn at any time during the dosing interval due to a flat concentration-time profile is not accurate for all dosing schedules. While phenytoin's long half-life does reduce peak-to-trough fluctuation compared to drugs with shorter half-lives, standardized trough sampling is still required for consistent and interpretable monitoring — particularly after dose changes when concentrations are still evolving toward a new steady state.
13. What is the active metabolite of eslicarbazepine acetate, how does it differ sterochemically from the active species produced by oxcarbazepine, and what pharmacokinetic property permits once-daily dosing?
A) Eslicarbazepine acetate is converted to R-licarbazepine by hepatic esterases; R-licarbazepine has a half-life of 6–8 hours requiring twice-daily dosing, and its R-stereochemistry confers greater CYP3A4 induction than oxcarbazepine's MHD mixture, making eslicarbazepine acetate more likely to reduce co-administered drug concentrations
B) Eslicarbazepine acetate undergoes spontaneous hydrolysis to oxcarbazepine in gastric acid; the two drugs are therefore pharmacokinetically equivalent after oral administration because they share the same active species (MHD mixture) and elimination half-life
C) Eslicarbazepine acetate is not a prodrug; it is active as the parent compound and is metabolized by CYP2C9 to an inactive R-hydroxyl metabolite with a half-life of 4 hours; once-daily dosing is possible because of a prolonged pharmacodynamic effect at the Nav channel that outlasts the plasma concentration
D) Eslicarbazepine acetate is hydrolyzed to the R-enantiomer of MHD (R-licarbazepine); R-licarbazepine has higher Nav channel affinity than the S-enantiomer produced preferentially by oxcarbazepine; its half-life of 20–24 hours supports twice-daily but not once-daily dosing
E) Eslicarbazepine acetate is hydrolyzed almost entirely to S-licarbazepine, the S-enantiomer of the monohydroxy derivative (MHD); S-licarbazepine has higher affinity for the inactivated Nav channel than the R-enantiomer predominant in oxcarbazepine's MHD mixture, and its half-life of approximately 20–24 hours supports once-daily dosing
ANSWER: E
Rationale:
Option E is correct. Eslicarbazepine acetate is a prodrug that is hydrolyzed after oral administration almost exclusively to S-licarbazepine — the S-enantiomer of the monohydroxy derivative (MHD). Oxcarbazepine, in contrast, is reduced by cytosolic ketoreductases to a mixture of both enantiomers (approximately 80% S-MHD and 20% R-MHD under normal enzymatic conditions, though this ratio is sometimes stated as a racemic mix in some sources; the key point is that oxcarbazepine produces a mixture while eslicarbazepine acetate produces primarily the S-enantiomer). The S-enantiomer (S-licarbazepine) has been shown to have higher affinity for the inactivated conformation of Nav channels than the R-enantiomer, providing the pharmacological rationale for the enantiomeric selectivity built into eslicarbazepine acetate's prodrug design. S-licarbazepine has an elimination half-life of approximately 20–24 hours — substantially longer than MHD produced from oxcarbazepine (9–11 hours) — and this half-life is sufficient to support once-daily dosing while maintaining therapeutic plasma concentrations throughout the dosing interval.
Option A: Option A is incorrect. Eslicarbazepine acetate is hydrolyzed primarily to S-licarbazepine, not R-licarbazepine. The R-enantiomer has lower Nav channel affinity and is not the primary active species. The described half-life of 6–8 hours is characteristic of oxcarbazepine's MHD, not of S-licarbazepine from eslicarbazepine acetate. Additionally, eslicarbazepine acetate has a lower enzyme-inducing potential than oxcarbazepine, not greater.
Option B: Option B is incorrect. Eslicarbazepine acetate does not undergo hydrolysis to oxcarbazepine in gastric acid. These are distinct chemical compounds with different prodrug conversion pathways — eslicarbazepine acetate is an ester that is hydrolyzed to S-licarbazepine, while oxcarbazepine is a keto compound reduced to a mixture of MHD enantiomers. They are not pharmacokinetically equivalent and differ in their active enantiomer composition and elimination half-life.
Option C: Option C is incorrect. Eslicarbazepine acetate is a prodrug and does not act as the parent compound. It has no significant direct Nav channel-blocking activity until hydrolyzed to S-licarbazepine. The described CYP2C9-mediated R-hydroxylation to a 4-hour half-life metabolite does not correspond to any established eslicarbazepine acetate metabolic pathway. Once-daily dosing is based on the pharmacokinetic half-life of S-licarbazepine (~20–24 hours), not on a prolonged pharmacodynamic effect outlasting plasma concentrations.
Option D: Option D is incorrect. Eslicarbazepine acetate produces the S-enantiomer, not the R-enantiomer, as its primary active metabolite — the description in this option is stereochemically reversed. Furthermore, S-licarbazepine's half-life of 20–24 hours does support once-daily dosing; this is in fact the established clinical advantage of eslicarbazepine acetate over oxcarbazepine (which requires twice-daily dosing because of MHD's shorter 9–11 hour half-life).
14. What is the molecular mechanism by which phenytoin and carbamazepine induce CYP enzymes, and what is the clinical significance of the 2–4 week time course for both the onset and offset of induction?
A) Phenytoin and carbamazepine are competitive inhibitors of CYP3A4 at low therapeutic concentrations; at higher concentrations, inhibition transitions to irreversible mechanism-based inactivation; inactivated enzyme must be replaced by de novo protein synthesis over 2–4 weeks, accounting for the delayed onset of the full interaction
B) Phenytoin and carbamazepine activate the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), which translocate to the nucleus and upregulate transcription of CYP1A2, CYP2C9, CYP2C19, CYP3A4, and UGT enzymes; full induction requires 2–4 weeks for new enzyme protein to accumulate; de-induction after drug discontinuation also takes 2–4 weeks as induced enzyme turns over — creating two windows of pharmacokinetic instability that require active monitoring
C) Phenytoin and carbamazepine stimulate release of hepatocyte growth factor (HGF) from stellate cells in the liver, which promotes hepatocyte proliferation and increases total hepatic CYP enzyme mass; induction develops over 2–4 weeks as new hepatocytes mature; de-induction is permanent unless drug therapy is resumed, because newly generated hepatocytes are not subject to downregulation
D) Enzyme induction by phenytoin and carbamazepine is complete within 72 hours of initiation because it occurs through post-translational stabilization of pre-existing CYP protein rather than transcriptional upregulation; the 2–4 week period mentioned in some references reflects the time for clinical interaction effects to become apparent due to slow redistribution of co-administered drugs between plasma and tissue compartments
E) Phenytoin and carbamazepine induce CYP enzymes exclusively in the intestinal wall (CYP3A4) but not in the liver; the 2–4 week time course reflects gradual turnover of intestinal epithelial cells; hepatic enzymes are unaffected, so drugs eliminated entirely by hepatic metabolism are not subject to these interactions
ANSWER: B
Rationale:
Option B is correct. Phenytoin and carbamazepine are among the most potent nuclear receptor agonists in clinical pharmacology. Both drugs activate the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) — ligand-activated nuclear receptors expressed in hepatocytes and intestinal epithelium. Upon activation, PXR and CAR translocate to the nucleus, dimerize with retinoid X receptor (RXR), and bind to response elements in the promoter regions of CYP1A2, CYP2C9, CYP2C19, CYP3A4, and multiple UGT enzyme genes, upregulating their transcription. New mRNA must be translated and new enzyme protein synthesized and incorporated into hepatic microsomes — a process that takes 2–4 weeks to reach a new steady state as newly synthesized enzyme accumulates to balance normal enzyme turnover. De-induction after drug discontinuation follows the same 2–4 week time course in reverse: as PXR/CAR activation is lost, induction of transcription ceases and existing induced enzyme protein undergoes normal turnover until baseline enzyme levels are restored. This means that patients who discontinue an inducing drug will have progressively rising plasma concentrations of co-administered drugs (e.g., warfarin, oral contraceptives, DOACs, lamotrigine) over the 2–4 weeks following discontinuation — a clinically dangerous period requiring proactive dose monitoring and adjustment.
Option A: Option A is incorrect. Phenytoin and carbamazepine are not CYP3A4 inhibitors at therapeutic concentrations, and they do not undergo transition from competitive inhibition to mechanism-based inactivation. They are transcriptional inducers operating through PXR and CAR. Mechanism-based (irreversible) CYP inactivation is the mechanism of drugs such as clarithromycin and mifepristone — not phenytoin or carbamazepine. The 2–4 week time course reflects transcriptional upregulation requiring new protein synthesis, not de novo protein replacement after irreversible inhibition.
Option C: Option C is incorrect. Phenytoin and carbamazepine do not stimulate hepatocyte growth factor secretion or promote hepatocyte proliferation as the mechanism of enzyme induction. CYP enzyme induction is a transcriptional event occurring within existing hepatocytes, not a proliferative expansion of hepatocyte mass. Furthermore, de-induction is not permanent — it reverses over 2–4 weeks after drug discontinuation as PXR/CAR transcriptional drive is removed and induced enzyme turns over.
Option D: Option D is incorrect. Enzyme induction by phenytoin and carbamazepine requires new protein synthesis and does not develop within 72 hours. Post-translational protein stabilization is not the established mechanism; transcriptional upregulation is. The 2–4 week induction period is well-documented from clinical studies of drug interactions with warfarin, oral contraceptives, and other substrates — it is not an artifact of slow drug redistribution.
Option E: Option E is incorrect. Phenytoin and carbamazepine induce CYP enzymes in both the liver and the intestinal wall, not exclusively intestinally. The hepatic component is quantitatively the more important contributor to systemic drug interactions because the liver handles the vast majority of systemic drug metabolism. Drugs eliminated entirely by hepatic metabolism are absolutely subject to induction-based drug interactions with phenytoin and carbamazepine — describing them as unaffected is clinically incorrect and could lead to serious therapeutic failures.
15. Which of the following correctly describes the complete pharmacokinetic profile of lacosamide — including oral bioavailability, protein binding, elimination half-life, primary metabolic pathway, and dose adjustment requirements?
A) Lacosamide has oral bioavailability of approximately 60–70%, protein binding of approximately 50%, and a half-life of 6–8 hours requiring three-times-daily dosing; it is metabolized by CYP3A4 to an active hydroxylated metabolite; dose reduction is required in moderate hepatic impairment but not in renal impairment because the active metabolite is hepatically eliminated
B) Lacosamide has oral bioavailability approaching 100%, protein binding of approximately 60%, and a half-life of 20–24 hours permitting once-daily dosing; it is not metabolized but excreted entirely unchanged by the kidneys; dose reduction is required in all patients with any degree of renal impairment proportional to the reduction in creatinine clearance
C) Lacosamide has oral bioavailability of approximately 75%, is highly protein-bound at approximately 90% to albumin, and has a half-life of 13 hours; it undergoes extensive first-pass hepatic metabolism by CYP2D6 to multiple active metabolites that contribute to its antiseizure activity; no dose adjustment is needed in either renal or hepatic impairment
D) Lacosamide has oral bioavailability of approximately 100% with no significant food effect, protein binding below 15%, and a half-life of approximately 13 hours supporting twice-daily dosing; it is metabolized by CYP2C19 to an inactive O-desmethyl metabolite with approximately 40% of the drug excreted unchanged renally; dose reduction is required in severe renal impairment (creatinine clearance below 30 mL/min) and moderate reduction is recommended in severe hepatic impairment
E) Lacosamide has oral bioavailability of approximately 100%, is minimally protein-bound, and has a half-life of 4–6 hours requiring three-times-daily dosing; it undergoes autoinduction of CYP2C19 analogous to carbamazepine's CYP3A4 autoinduction, with the half-life shortening from 13 hours at initiation to 4 hours at steady state
ANSWER: D
Rationale:
Option D is correct. Lacosamide has an exceptionally favorable pharmacokinetic profile that distinguishes it from older sodium channel anti-seizure drugs. Oral bioavailability is approximately 100%, with no clinically significant food effect, producing reliable and predictable plasma concentrations after oral dosing. Protein binding is less than 15% — in sharp contrast to phenytoin (~90%) and carbamazepine (~80%) — which eliminates protein displacement interactions and makes free drug monitoring unnecessary even in hypoalbuminemic patients. The elimination half-life is approximately 13 hours, consistent with twice-daily oral dosing. Metabolism occurs primarily via CYP2C19-mediated O-demethylation to a pharmacologically inactive O-desmethyl metabolite; approximately 40% of the parent drug is excreted unchanged in the urine. Because lacosamide is not a significant inducer or inhibitor of CYP enzymes, it does not substantially alter the plasma concentrations of co-administered drugs. Dose reduction is required in patients with severe renal impairment (creatinine clearance below 30 mL/min) due to reduced renal elimination of the unchanged fraction, and moderate dose reduction is recommended in severe hepatic impairment due to effects on CYP2C19-mediated metabolism.
Option A: Option A is incorrect. Lacosamide's oral bioavailability is approximately 100%, not 60–70%. Its protein binding is less than 15%, not approximately 50%. Its half-life is approximately 13 hours — not 6–8 hours — and supports twice-daily rather than three-times-daily dosing. The primary metabolic enzyme is CYP2C19, not CYP3A4, and the O-desmethyl metabolite is inactive, not pharmacologically active. Dose adjustment is required for renal impairment because approximately 40% of lacosamide is excreted unchanged renally.
Option B: Option B is incorrect. While the ~100% bioavailability is correct, lacosamide's protein binding is approximately 15% or less — not approximately 60%. Its half-life is 13 hours, not 20–24 hours; the 20–24 hour half-life belongs to S-licarbazepine from eslicarbazepine acetate. Lacosamide is not excreted entirely unchanged; approximately 40% undergoes CYP2C19-mediated O-demethylation, and dose reduction is not required proportionally at all levels of renal impairment — only in severe renal impairment (CrCl below 30 mL/min).
Option C: Option C is incorrect. Lacosamide is not approximately 75% bioavailable; it approaches 100%. It is not 90% albumin-bound — its defining pharmacokinetic advantage is minimal protein binding below 15%. CYP2D6 is not a significant enzyme in lacosamide metabolism; CYP2C19 is the primary pathway. Lacosamide does not have active metabolites; the O-desmethyl product is inactive. Dose adjustment is required in severe renal and hepatic impairment, contrary to the claim that no adjustment is needed.
Option E: Option E is incorrect. While the approximately 100% bioavailability and minimal protein binding are correctly stated, lacosamide does not have a half-life of 4–6 hours and does not undergo autoinduction. Its half-life is approximately 13 hours and is stable throughout therapy. Autoinduction of CYP2C19 with progressive half-life shortening is not an established feature of lacosamide pharmacokinetics — this phenomenon is specific to carbamazepine (CYP3A4 autoinduction).
16. What is the pharmacokinetic mechanism by which carbamazepine reduces lamotrigine plasma concentrations, and what clinical risk must be anticipated when carbamazepine is subsequently discontinued in a patient stabilized on both drugs?
A) Carbamazepine inhibits intestinal P-glycoprotein efflux, paradoxically increasing lamotrigine absorption and raising lamotrigine plasma concentrations; when carbamazepine is discontinued, P-glycoprotein recovers over 2–4 weeks and lamotrigine concentrations fall, risking breakthrough seizures rather than toxicity
B) Carbamazepine inhibits CYP2D6, the enzyme responsible for lamotrigine N-glucuronidation; reduced glucuronidation slows lamotrigine elimination, raising its plasma concentration; when carbamazepine is stopped, CYP2D6 recovers within 24 hours and lamotrigine falls rapidly to subtherapeutic levels
C) Carbamazepine induces UGT1A4 (and to a lesser extent CYP3A4), the primary enzyme responsible for lamotrigine glucuronidation, reducing lamotrigine plasma concentrations by approximately 40–50% at a fixed dose; when carbamazepine is subsequently discontinued, UGT induction wanes over 2–4 weeks and lamotrigine concentrations rise progressively, potentially reaching toxic levels if the lamotrigine dose is not proactively reduced
D) Carbamazepine displaces lamotrigine from UGT1A4 binding sites through competitive substrate inhibition, transiently reducing lamotrigine glucuronidation at the start of combined therapy; this effect resolves within 7–10 days as enzyme upregulation compensates, and no dose adjustment is required when carbamazepine is later discontinued
E) Carbamazepine has no pharmacokinetic interaction with lamotrigine; the dose adjustment described in clinical practice reflects the pharmacodynamic synergy between the two drugs, which requires empirical dose reduction of both agents when combined to avoid additive CNS toxicity from dual sodium channel blockade
ANSWER: C
Rationale:
Option C is correct. Lamotrigine is eliminated primarily by UGT1A4-mediated glucuronidation to an inactive N-2-glucuronide, with a minor contribution from CYP3A4. Carbamazepine is a potent inducer of both UGT enzymes and CYP3A4 via PXR and CAR activation. When carbamazepine is co-administered, UGT1A4 activity is substantially upregulated, accelerating lamotrigine glucuronidation and reducing lamotrigine plasma concentrations by approximately 40–50% at any given dose. This means that patients on combined carbamazepine-lamotrigine therapy require substantially higher lamotrigine doses to maintain therapeutic concentrations than would be needed on lamotrigine monotherapy. The bidirectional clinical implication is critical: when carbamazepine is initiated in a patient already on lamotrigine, lamotrigine concentrations fall progressively over 2–4 weeks (risking breakthrough seizures unless the lamotrigine dose is increased proactively), and when carbamazepine is subsequently discontinued, UGT induction wanes over the same 2–4 week period, causing lamotrigine concentrations to rise substantially toward and potentially above the toxic threshold — producing diplopia, dizziness, ataxia, and rash unless lamotrigine doses are proactively reduced.
Option A: Option A is incorrect. Carbamazepine does not inhibit P-glycoprotein efflux in the intestine — it is a P-glycoprotein inducer. The pharmacokinetic direction of the carbamazepine-lamotrigine interaction is that carbamazepine decreases lamotrigine plasma concentrations (by inducing UGT enzymes), not increases them. The risk on carbamazepine discontinuation is therefore lamotrigine toxicity from rising concentrations, not breakthrough seizures from falling concentrations.
Option B: Option B is incorrect. Lamotrigine is not metabolized by CYP2D6; its primary elimination pathway is UGT1A4-mediated glucuronidation. CYP2D6 plays essentially no role in lamotrigine metabolism. Carbamazepine is a UGT enzyme inducer, not a CYP2D6 inhibitor. The enzyme induction half-life is 2–4 weeks, not 24 hours — rapid recovery of enzyme activity within one day does not occur after discontinuation of a transcriptional inducer.
Option D: Option D is incorrect. The interaction between carbamazepine and lamotrigine is not a transient competitive substrate interaction at UGT1A4 that self-resolves within 7–10 days. It is a sustained transcriptional induction of UGT enzyme synthesis that persists for the entire duration of carbamazepine therapy and does not resolve spontaneously while carbamazepine continues. A dose adjustment when carbamazepine is stopped is absolutely required, contrary to the claim.
Option E: Option E is incorrect. There is a well-established pharmacokinetic interaction between carbamazepine and lamotrigine — not merely a pharmacodynamic one. The interaction is mechanistic and quantifiable (40–50% reduction in lamotrigine levels), and clinical dose adjustments are based on this pharmacokinetic change, not on empirical reduction for additive CNS toxicity. Denying the pharmacokinetic interaction would lead to systematic under-treatment of lamotrigine when carbamazepine is co-administered and failure to anticipate lamotrigine toxicity on carbamazepine withdrawal.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.